bioMérieux, Inc., a leading global player in the field of in vitro diagnostics, is headquartered in the United States and operates extensively across North America and beyond. Founded in 1963, the company has established itself as a pioneer in microbiology and immunoassays, providing innovative solutions that enhance patient care and public health. With a diverse portfolio of products and services, bioMérieux focuses on areas such as infectious disease diagnostics, industrial microbiology, and molecular biology. Their unique offerings, including rapid diagnostic tests and automated systems, set them apart in the competitive landscape. Recognised for their commitment to quality and innovation, bioMérieux has achieved significant milestones, solidifying their market position as a trusted partner in healthcare and laboratory settings worldwide.
How does bioMérieux, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
bioMérieux, Inc.'s score of 73 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
bioMérieux, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of bioMérieux S.A., which cascades its emissions data and climate commitments down to its subsidiaries. As of now, bioMérieux, Inc. has not outlined any specific reduction targets or initiatives in its own reporting. However, it is important to note that the climate commitments and performance metrics are inherited from bioMérieux S.A. at the first cascade level. This includes participation in initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), which are aimed at reducing greenhouse gas emissions and enhancing transparency in climate-related performance. While specific emissions figures are not provided, bioMérieux, Inc. is part of a broader corporate strategy focused on sustainability and climate action, reflecting the industry's increasing emphasis on reducing carbon footprints and addressing climate change.
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 31,000,000 | 00,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000 | 00,000 |
| Scope 2 | 35,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 241,000,000 | 000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000 | 0,000,000 |
bioMérieux, Inc.'s Scope 3 emissions, which increased by 0% last year and decreased by approximately 100% since 2018, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 3% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 54836% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
bioMérieux, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.